Researchers have developed a dynamic clinical calculator that estimates conditional recurrence-free survival after total neoadjuvant therapy in patients with rectal cancer.
Robotic surgery resulted in improved quality of resection, faster postoperative recovery, fewer postoperative and intraoperative complications, shorter hospital stays, and decreased surgical trauma.
Adding galunisertib to neoadjuvant chemoradiotherapy may improve responses in patients with locally advanced rectal cancer.
Patients treated with radiotherapy had a greater risk of second primary cancer when compared with patients who underwent surgery or surveillance.
Overall, adjuvant chemotherapy does not appear to increase the risk of second cancers for patients with stage III-IV colon cancer.
Researchers developed a strategy for providing rectal cancer survivors with dietary guidance and posttreatment care.
A rectum-preserving strategy may produce outcomes similar to standard resection-based treatment for locally advanced rectal adenocarcinoma.
A meta-analysis showed a significant improvement in overall survival, but not disease-free survival, with laparoscopic surgery.
There was no significant difference in disease-free survival, metastasis-free survival, or locoregional recurrence.
Carcinoembryonic antigen (CEA) testing may fail to detect disease recurrence in patients with rectal cancer who have negative CEA at baseline.
